


<p>GA 101003666 Start date: 01/04/20 End Date: 31/03/22</p>	
<p>Project Title</p>	<p>OPENCORONA</p>
<p>WP number, deliverable number, and Title</p>	<p>WP8 D8.7 Communication and Dissemination Plan</p>
<p>Responsible partner name and contact</p>	<p>Partner number: 1 Organisation: Karolinska Institutet Name: Hanna Gador Email: hanna.gador@ki.se</p>
<p>Nature R-Report P-Prototype D-Demonstrator O=-Other</p>	<p>Report</p>
<p>Dissemination level PU-public PP-restricted to otherprogramme participants RE-restricted to a group of partners CO-only for consortium members</p>	<p>CO</p>
<p>Delivery Month Planned</p>	<p>M6 – 30 September 2020</p>
<p>Actual delivery date (dd/mm/yy)</p>	<p>18 November 2020</p>



Description of deliverable

- **COMPLETED**

- We have established a Communication and Dissemination Plan for the communication for the OPENCORONA consortium and towards our stakeholders. The Communication and Dissemination Plan v1.0 has been uploaded to the Consortium internal web.

- **ANNEXES**

- Communication and Dissemination Plan for the OPENCORONA project.



Communication and Dissemination Plan

Project Acronym:	OPENCORONA
Grant Agreement No:	101003666
Project Duration:	1 April 2020 – 31 March 2022
Responsible Partner:	Karolinska Institutet Name: Hanna Gador E-mail: hanna.gador@ki.se
Document version	
Version 1	M6

Document History			
Version	Date	Author	Description
1.0	November 2020	Hanna Gador	Plan established

Contents

Executive summary	2
Acronyms.....	2
Introduction.....	2
Claim	3
Contribution to EC.....	3
Project Hashtags.....	3
Project vision	3
Short summary	3
General Project Objectives.....	3
Stakeholders.....	4
Internal	4
External.....	4
Our Message.....	4
External.....	4
Scientific community	4
	1



Clinicians.....	4
Industry.....	4
Regulators.....	5
General Public	5
Patient Organizations	5
External communication and dissemination channels.....	5
Documentation and reporting of communication and dissemination.....	6
Consortium Communication tools	6
Internal communication	6
External communication	7
Social Media	7
Information bank.....	7

Executive summary

A project performance and success rate can be very high even though it can go through struggle to reach out to the community and stakeholders. In order to raise the project to the next level a plan for the communication and dissemination is vital and of importance.

The Communication and Dissemination plan is established according to the OPENCORONA project Grant Agreement no 101003666 in order to provide a plan for the consortium communication both within the consortium as well as outside the consortium with the hope to raise the collaboration opportunities and results for the project and funding agency.

Acronyms

OPENCORONA	Rapid therapy development through Open nCoronavirus Vaccine Platform
GA	Grant Agreement No 101003666
CA	Consortium Agreement for the OPENCORONA project
WP	Work Package according to Grant agreement Annex 1
PSM	Project Steering Committee
PC	Project Coordinator
PMO	Project Management Office, the coordinators management team
KI Box	Coordinator cloud-based sharing tool
Web	Project website https://ki.se/en/research/opencorona

Introduction

The aim of this plan is to provide the consortium with initial guidelines for communication and dissemination purpose. The content is by no means exhaustive and depends on each partners



participation, engagement, and support in the communication with press, information for website, social media channels and networks to enlighten the project scope and activities.

Claim

Contribution to EC

Beside the project acronym OPENCORONA and title “Rapid therapy development through Open nCoronavirus Vaccine Platform “ EC shall always in any communication and/or dissemination be mentioned as official funding agency acknowledgement.



This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 101003666

Project Hashtags

For any project related communication in social media please use the following Hashtags #opencorona, #VaccinesWork, #EuropeansAgainstCOVID19, #COVID19, #StrongerTogether #H2020

Project vision

The vision for the OPENCORONA project is to develop a vaccine against COVID-19 that gives durable antibody and T cell responses that also are active also against future corona viral outbreaks from the animal kingdom.

Short summary

No approved human coronavirus immunotherapy or vaccine exists. Thus, speed in therapy and vaccine development is critical. Genetic analysis shows that the SARS-CoV-2 envelope and receptor binding domain only has a 75% homology with other human coronaviruses. Thus, existing immunotherapies and vaccine candidates against other coronaviruses, such as SARS, will not be useful against SARS-CoV-2. We will use the DNA vaccine platform as this is currently the most rapid and robust vaccine platform. We have generated several chimeric SARS-CoV-2 genes and will select for the most potent DNA vaccine/immunotherapy candidate delivered by *in vivo* electroporation that protects against SARS-CoV-2 infection and/or disease in animal models and take this to phase I clinical testing.

The partners in the consortium have done this before and all know-how for reliable development is present. KI and FoHM will develop vaccine candidates and infectious models, JLU will test candidates for over-activation of innate immunity, IGEA will provide a CE marked device for *in vivo* electroporation in humans. Cobra will produce HQ plasmid to be used in toxicological studies and GMP plasmid for the phase I clinical study, Adlego will perform toxicological testing according to GLP, and Karolinska will write the IB (Investigator’s brochure) and IMPD (Investigational Medicinal Products Dossier), file with ethics committee and EMA, and perform a phase I clinical trial of the immunotherapy/vaccine in healthy volunteers. All these tasks are within the expertise that the partners do every day. Thus, this is truly realistic.

General Project Objectives

For general communication purpose the project objectives can be summarized as:



- Design and select the most potent vaccine gene candidate that activates and immune response that protect against COVID-19 and new coronaviruses that may jump from animals to humans
- Develop the vaccine candidate primarily as a DNA vaccine delivered by a new device for in vivo electroporation
- Test the vaccine for ability to protect against COVID-19 in animal models
- Perform clinical development and apply for a phase I clinical trial in humans
- Phase 1 clinical testing of the vaccine in humans

Stakeholders

The term describes in general words the different groups that affect, or might be affected, by the OPENCORONA and its activities.

The stakeholders can be defined as follows:

Internal

- Partners of the OPENCORONA consortium
- Advisory board of the OPENCORONA consortium

External

- Scientific community
- Clinicians
- Industry
- Regulators
- General Public
- Patient Organizations

Our Message

Our project creates allot of interest from our external public. In order to serve a start, point when you address the specific groups the common message below is of interest for your communication.

External

Scientific community

Within the OPENCORONA project we are following the Open Data policy and aim for open access scientific publications as early on as possible.

Our results are presented through the OPENCORONA website. We are all in this together.

Clinicians

Within the OPENCORONA project we focus on a solution for a safe and effective DNA vaccine to be distributed by in vivo electroporation.

To initiate a clinical Phase 1 study at the end of the OPENCORONA project.

Industry

Within the OPENCORONA project we focus on a solution for a safe and effective DNA vaccine to be distributed by in vivo electroporation.



Regulators

OPENCORONA aims to develop a DNA vaccine by involving the regulators early on to perform a clinical Phase 1 study.

OPENCORONA addresses the urgent need to find a vaccine for SARS -Cov-2 infection and halt the pandemic.

General Public

The research done on the OPENCORONA project aims to create a vaccine that will be useful for SARS-Cov-2 and for a long-term control of SARS-CoV-2 and the COVID-19pandemia.

Our aim for the OPENCORONA project is that our vaccine will help not just for the current SARS-Cov - 2 but also for future coronaviruses.

Patient Organizations

Our aim for the OPENCORONA project is that our vaccine will help not just for the current Sars-Cov -2 but also for future coronaviruses.

External communication and dissemination channels

Targeted stakeholder's	Communication Channels
Scientific community	Scientific conferences and symposium Open Access publications Press releases Project website Newsletter Visual media (tv, interviews) Communication material (articles, poster, factsheet) Social media
Clinicians	Press releases Project website Newsletter Visual media (tv, interviews) Communication material (articles, poster, factsheet) Social media
Industry	Scientific conferences and symposium Press releases Project website Newsletter Visual media (tv, interviews) Communication material (articles, poster, factsheet) Social media Advisory board members
Regulators	Press releases Meetings Social media Communication material (articles, poster, factsheet)
General Public	Press releases Project website Newsletter Visual media (tv, interviews)



	Communication material (articles, poster, factsheet) Social media
Patient Organizations	Press releases Project website Newsletter Visual media (tv, interviews) Communication material (articles, poster, factsheet) Social media Clinical study Patient panel at clinical site

Documentation and reporting of communication and dissemination

Dissemination material and Public digital research data is saved in the KI Box and has to be included in the periodic reporting for the project. Each partner is asked to themselves upload in the OPENCORONA Public information the information that can be publicly shared.

Consortium Communication tools

Internal communication

Our internal communication and work tool are the

2 KI boxes <https://ki.app.box.com>

1. OPENCORONA Consortium – Confidential

<https://ki.app.box.com/folder/108988039563>

The Consortium – Confidential box is only for the consortium members and will contain the work material we use as well as supporting and regulating documents for the OPENCORONA project.

2. OPENCORONA Public information

<https://ki.app.box.com/folder/108977415505>



The screenshot displays a OneDrive interface for a folder named 'OPENCORONA Public information'. The left sidebar shows navigation options like 'All files', 'Recents', 'Synced', 'Bin', 'Notes', and 'Favourites'. The main area shows a table of files:

Name	Updated	Size
Public digital research data for OPE...	6 Jul 2020 by Hanna...	0 Files
Opencorona in media	1 Jun 2020 by Gusta...	0 Files

The right-hand 'Sharing' pane lists the following users and roles:

- Hanna Gador (Owner)
- Lars Frelin (Co-owner)
- Matti Sällberg (Co-owner)
- Gustaf Ahlén (Co-owner)
- Ida Kettley (Editor)
- +12 People (Externally shared)

Additional sharing options include 'Shared Link Create Link' and 'File request Create Link'. A 'Share this folder' button is located at the bottom of the sharing pane.

For invitation to either communication tools contact the management team.

External communication

We have a project website for external communication

<https://ki.se/en/research/opencorona>

Use and spread our social media and website!

To add results, news, data to the website or social media channels contact lars.frelin@ki.se copy to matti.sallberg@ki.se and Gustaf.ahlen@ki.se

Social Media

<https://www.facebook.com/opencorona/>

<https://www.instagram.com/opencorona/>

<https://twitter.com/opencorona>

<https://www.linkedin.com/company/opencorona>

Information bank

<https://sv.wikipedia.org/wiki/Opencorona>

